Previous close | 0.8500 |
Open | 0.3800 |
Bid | 0.0000 |
Ask | 1.0000 |
Strike | 25.00 |
Expiry date | 2024-07-19 |
Day's range | 0.3800 - 0.8500 |
Contract range | N/A |
Volume | |
Open interest | 84 |
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has started shipping its new Xenium Prime 5K Pan-Tissue and Pathways panel. The new panel features an enhanced chemistry to increase plex by an order of magnitude while delivering excellent per-gene sensitivity, improved specificity and spatial fidelity, integrated multimodal cell segmentation and industry-leading speed and throughput.
Key Insights 10x Genomics to hold its Annual General Meeting on 11th of June Total pay for CEO Serge Saxonov includes...
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of its Xenium Prime 5K Pan-Tissue and Pathways panel. The new assay features an enhanced chemistry to increase plex by an order of magnitude while delivering excellent per-gene sensitivity, improved specificity and spatial fidelity, integrated multimodal cell segmentation, and industry-leading speed and throughput.